Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2014

View Archived Issues

BeiGene reports development of BRD4 inhibitors

Antiobesity hydrogel shows promise in proof-of-concept study

Ciclofilin Pharmaceuticals receives support for preclinical development of CPI-431-32

Novel RSV vaccines disclosed by Crucell Holland

Merck & Co. divulges novel SYK inhibitors

Qidong Gaitianli Medicines reports antitumor proteoglycans isolated from fungus

Actelion discloses new antibacterial quinolone derivatives

U.S. researchers present novel NOX2 inhibitors

Phase I results of a tetravalent purified inactivated dengue vaccine

Pernix Therapeutics submits supplemental NDA for Treximet

Genetic variant linked to intracranial major artery stenosis/occlusion

Dicerna forms licensing agreement with Tekmira for PH1 program

Advanced Cell Technology changes name

PATH Malaria Vaccine Initiative, NIAID and Mymetics form collaboration to develop malaria vaccine

GlycoMimetics reports topline phase I results for GMI-1271

Eylea approved in Japan for diabetic macular edema

ProACT study evaluates procalcitonin levels in patients with lung infections

Tumor antigen-targeted IL-15 complex eliminates lymphoma cells

China publishes draft biosimilar guidance

DiaMedica releases topline phase IIa results for DM-199 in type 2 diabetes

Actavis to acquire Allergan

NeoStem reports initial data from phase II study of stem cell therapy in acute myocardial infarction

PDL BioPharma concludes revenue interest agreement with AxoGen

Vacc-4x and lenalidomide increase CD4 count in phase I/II trial in patients with HIV infection

Clovis Oncology and GSK to collaborate on phase I/II trial of rociletinib and trametinib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...